Your session is about to expire
← Back to Search
Senicapoc for Dehydrated Stomatocytosis
Study Summary
This trial is for a disorder called Dehydrated Stomatocytosis, which is a genetic disorder that causes chronic hemolysis, variable anemia, and erythrocyte dehydration. The goal of this trial is to see if Senicapoc, a drug that has been shown to be safe with limited side-effects, can help treat this disorder.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have severe anemia with a very low hematocrit level.I am not pregnant or breastfeeding.I have kidney issues, indicated by high creatinine or need for dialysis.My liver tests are within normal limits.I have dehydrated stomatocytosis with a confirmed KCNN4 mutation.You have a serious medical condition or abnormal lab results that could make it risky for you to take part in the study or use senicapoc, according to the doctor in charge of the study.I have blood issues related to dehydrated stomatocytosis, meeting at least 3 of the specific criteria listed.I have received a red blood cell transfusion in the last 90 days.I have a specific KCNN4 gene mutation sensitive to senicapoc.I had a stroke or mini-stroke in the last 2 weeks.I have not been hospitalized for surgery, infection needing IVs, or major bleeding in the last 30 days.You are currently using illegal drugs, or you have a problem with alcohol.I am 21 years old or older.
- Group 1: Treatment
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this experiment still recruiting participants?
"Affirmative. Clinicaltrials.gov reveals that the medical study, which was first posted on April 15th 2021, is actively recruiting participants. 6 individuals from one centre must be enrolled in order to complete the trial."
Are there any studies that have utilized the drug ICA-17043 (Senicapoc; 2,2-bis-(4-fluorophenyl)-2-phenylacetamide) in their research?
"Presently, there are two clinical trials for Senicapoc (ICA-17043; 2,2-bis-(4-fluorophenyl)-2-phenylacetamide) with no Phase 3 studies being conducted. There is a concentration of these studies in Boston, MA but three medical facilities across the United States have been approved to run trials for this drug molecule."
How many participants are participating in this experiment?
"Affirmative. Information accessible on clinicaltrials.gov verifies that this research effort, initially posted to the website in April 2021, is currently enrolling participants. The study requires 6 individuals from a single location."
Share this study with friends
Copy Link
Messenger